Publications
442
Citations
16,170
Est. group size
~94
Recurring co-author estimate
Active years
34
Publishing since 1993
Zihai Li's research focuses on tumor immunology and cancer immunotherapy, examining how immune cells like T cells and NK cells interact with tumors and how cellular stress pathways (such as protein misfolding and mitochondrial stress) affect immune cell function. The work spans basic mechanisms of immune evasion and exhaustion as well as translational efforts including CAR-T cell therapies, checkpoint blockade combinations, and clinical trials for cancers like glioblastoma, melanoma, and lung cancer.
Publication output has grown substantially over the past decade, rising from about 20 papers per year in 2017-2020 to a peak of 87 in 2023 and remaining high through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 2928: KRAS inhibition-induced GSDME-mediated pyroptosis and its augmentation by LAT1 inhibition in KRAS-mutant lung cancer
Cancer Research · 2026
- Recent advances in therapeutic strategies for non-small cell lung cancer
Journal of Hematology & Oncology · 2025
- Proteotoxic stress response drives T cell exhaustion and immune evasion
Nature · 2025
- Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
Cancer Discovery · 2025
- Sex differences in bladder cancer: understanding biological and clinical implications
Biology of Sex Differences · 2025
- Multi-scaled transcriptomics of chronically inflamed nasal epithelium reveals immune-epithelial dynamics and tissue remodeling in nasal polyp formation
Immunity · 2025
- The new microbiome on the block: challenges and opportunities of using human tumor sequencing data to study microbes
Nature Methods · 2025
- USP30 inhibition augments mitophagy to prevent T cell exhaustion
Science Advances · 2025
- Rapid assay development for low input targeted proteomics using a versatile linear ion trap
Nature Communications · 2025
- HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors
Journal of Hematology & Oncology · 2025
- Targeting TGFβ docking receptor glycoprotein A repetitions predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma
Neuro-Oncology · 2025
- The NAE1-mediated neddylation operates as an essential post-translational modification checkpoint for effector CD8 <sup>+</sup> T cells
Proceedings of the National Academy of Sciences · 2025
- A novel TLR4 accessory molecule drives hepatic oncogenesis through tumor-associated macrophages
Cancer Letters · 2025
- Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas
Neuro-Oncology Advances · 2025
- CNPY2 in Solid Tumors: Mechanisms, Biomarker Potential, and Therapeutic Implications
Biology · 2025
- The Journal of Immunology×19
- Regular and Young Investigator Award Abstracts×16
- Journal of Hematology & Oncology×14
- bioRxiv (Cold Spring Harbor Laboratory)×13
- Cancer Research×12
- Andreas Wieland
Medicine · The Ohio State University
- No‐Joon Song
Medicine · The Ohio State University
- Yoshinobu Koguchi
Medicine · The Ohio State University
- Tarah J. Ballinger
Medicine · Indiana University
- Nandini Acharya
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile